atai is a Berlin, New York, and London based biotech company builder leveraging a decentralized, data-driven platform model with the aim of ultimately healing mental health disorders. We are dedicated to bringing innovation to mental healthcare, a field that has seen little progress since the development of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) in the 1980s and 1990s, respectively.
From a drug development perspective, ATAI sees significant potential in 5HT2A agonists, atypical opioids, as well as drugs that act on the glutamatergic and GABAergic systems. In contrast to traditional neuropsychiatric drug development, we cultivate early-stage polypharmacological drugs that impact key mental health biomarkers and have been de-risked, either by anecdotal evidence or off-label clinical use.
We now have over 13 companies in our portfolio developing innovative solutions in mental healthcare, including COMPASS Pathways (psilocybin for treatment-resistant depression), DemeRx (ibogaine for opioid use disorder), and EntheogeniX (leveraging AI and computational biophysics to develop the next generation of psychedelics).